Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Ossenkoppele, G.J., Breems, D.A., Stuessi, G., Norden, Y. van, Bargetzi, M., Biemond, B.J., Borne, P.A. von dem, Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J.J.J.W., Jaspers, A., Jongen-Lavrencic, M., Jongh, E. de, Klein, S.K., Klift, M. van der, Kooy, M.V., Maertens, J., Micheaux, L., Poel, M.W.M. van der, Rhenen, A. van, Tick, L., Valk, P., Vekemans, M.C., Velden, W.J.F.M. van der, Weerdt, O. de, Pabst, T., Manz, M., Lowenberg, B., Havelange, Moors, I., Obberg, F. van, Maertens, J.A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Gjertsen, B.T., Passweg, J., Heim, D., Giovanni, S., Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M.G., Loosdrecht, A. van de, Janssen, J.J.W.M., Esser, J.W.J. van, Brouwer, R.E., Lammeren-Venema, D. van, Levin, M.D., Tick, L.W., Legdeur, M.C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J.H., Schouten, H.C., Cornelissen, J., Wouters, B., Raaijmakers, H.G.M., Kuball, J., Dutch-Belgian Hemato-Oncology, Swiss Grp Clinical Canc Res SAKK
Publikováno v:
Leukemia, 1751-1759. Nature Publishing Group
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
Contains fulltext : 225470.pdf (Publisher’s version ) (Closed access) More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard
Autor:
Elizabeth A. Raetz, Amrana Quereshi, M. Zwaan, Nirali N. Shah, Keith J. August, Mignon L. Loh, Susan R. Rheingold, Luciano Dalla-Pozza, Richard Sposto, Jean-Pierre Bourquin, Maryalice Stetler-Stevenson, Deepa Bhojwani, Constance M. Yuan, Sarah Alexander, Paul G. Schlegel, Aurelie Cabannes, Jennifer L. McNeer, Maureen M. O'Brien, Vilmarie Rodriguez, Claudia Rossig
Publikováno v:
Leukemia, 33(4), 884-892. Nature Publishing Group
Leukemia, vol 33, iss 4
Leukemia
Leukemia, vol 33, iss 4
Leukemia
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/ref
Autor:
Johan Maertens, W Zeijlemaker, Alexander N Snel, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, D Veldhuizen, Angèle Kelder, Bob Löwenberg, Peter J. M. Valk, Jacqueline Cloos, Frank Preijers, Yvonne J M Oussoren-Brockhoff, Gerrit Jan Schuurhuis, Dimitri Breems, Jannemieke C Carbaat-Ham, Markus G. Manz, Willemijn J Scholten, Mojca Jongen-Lavrencic, Tim Grob, Rosa Meijer, Jennichjen Slomp, Thomas Pabst, Diana Hanekamp, Vincent H.J. van der Velden
Publikováno v:
Leukemia, 33, 5, pp. 1102-1112
Zeijlemaker, W, Grob, T, Meijer, R, Hanekamp, D, Kelder, A, Carbaat-Ham, J C, Oussoren-Brockhoff, Y J M, Snel, A N, Veldhuizen, D, Scholten, W J, Maertens, J, Breems, D A, Pabst, T, Manz, M G, van der Velden, V H J, Slomp, J, Preijers, F, Cloos, J, van de Loosdrecht, A A, Löwenberg, B, Valk, P J M, Jongen-Lavrencic, M, Ossenkoppele, G J & Schuurhuis, G J 2019, ' CD34 + CD38 − leukemic stem cell frequency to predict outcome in acute myeloid leukemia ', Leukemia, vol. 33, no. 5, pp. 1102-1112 . https://doi.org/10.1038/s41375-018-0326-3
Leukemia, 33(5), 1102-1112. Nature Publishing Group
Leukemia, 33, 1102-1112
Zeijlemaker, W, Grob, T, Meijer, R, Hanekamp, D, Kelder, A, Carbaat-Ham, J C, Oussoren-Brockhoff, Y J M, Snel, A N, Veldhuizen, D, Scholten, W J, Maertens, J, Breems, D A, Pabst, T, Manz, M G, van der Velden, V H J, Slomp, J, Preijers, F, Cloos, J, van de Loosdrecht, A A, Löwenberg, B, Valk, P J M, Jongen-Lavrencic, M, Ossenkoppele, G J & Schuurhuis, G J 2019, ' CD34 + CD38 − leukemic stem cell frequency to predict outcome in acute myeloid leukemia ', Leukemia, vol. 33, no. 5, pp. 1102-1112 . https://doi.org/10.1038/s41375-018-0326-3
Leukemia, 33(5), 1102-1112. Nature Publishing Group
Leukemia, 33, 1102-1112
Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict outcome in acute myeloid leukemia (AML). We introduce and validate a post-treatment approach of leukemic stem cell (LSC) assessment for prediction of outcome
Autor:
Ingrid M. Ariës, Edwin Cuppen, Martin A. Horstmann, C. van de Ven, Christian M. Zwaan, Elisabeth M.P. Steeghs, V de Haas, M L den Boer, Rob Pieters, Nicolle Besselink, Marco J. Koudijs, H A de Groot-Kruseman, Isabel S. Jerchel, Alex Q. Hoogkamer, Judith M. Boer, Aurélie Boeree, G Escherich
Publikováno v:
Leukemia, 32(4), 931. Nature Publishing Group
Leukemia, 32(4), 931-940. Nature Publishing Group
Leukemia
Leukemia, 32(4), 931-940. Nature Publishing Group
Leukemia
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defin
Autor:
Shaji Kumar, Kenneth Anderson, Chor S. Chim, Sergio Giralt, Morie A. Gertz, P. G. Richardson, Gordon Cook, M.V. Mateos, Xavier Leleu, Robert Z. Orlowski
Publikováno v:
Leukemia
Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM relapse/progression. Recent major randomized controlled trials (RCTs) showed widely varyin
Autor:
Zita Borbényi, Suddhasatta Acharyya, Karen W.L. Yee, Je-Hwan Lee, Massimo Breccia, S. Ide, Árpád Illés, Alan Macwhannell, Carlos Graux, Miklos Egyed, Nancy Zhu, David Valcárcel, James D. Cavenagh, Reinhard Stauder, Huda Salman, Daniel J. DeAngelo, Mikkael A. Sekeres, M. Marker, Oliver G. Ottmann, G. Garcia-Manero, Lucien Gazi, Pierre Fenaux
Publikováno v:
Leukemia
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
Autor:
Eunice S. Wang, Deedra Nicolet, Andrew J. Carroll, A-K Eisfeld, Clara D. Bloomfield, Christopher J. Walker, Shelley Orwick, Jonathan E. Kolitz, Richard Stone, James S. Blachly, A de la Chapelle, John C. Byrd, Karl Kroll, Jessica Kohlschmidt, Krzysztof Mrózek, Bayard L. Powell
Publikováno v:
Leukemia
Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific
Autor:
E. De Bruyne, Lucienne Michaux, Cecilia Mancini, Iwona Wlodarska, Karin Vanderkerken, H Lemmens, Emanuela Garelli, Pieter Sonneveld, Isabel J.F. Hofman, Ellen Geerdens, Michel Delforge, M. van Duin, Anna Aspesi, K. De Keersmaecker, Laura Fancello, George Mulligan, Peter Vandenberghe
Publikováno v:
Leukemia, 31(8), 1706-1714. Nature Publishing Group
Leukemia
Leukemia
Chromosomal region 1p22 is deleted in ≥20% of multiple myeloma (MM) patients, suggesting the presence of an unidentified tumor suppressor. Using high-resolution genomic profiling, we delimit a 58 kb minimal deleted region (MDR) on 1p22.1 encompassi
Autor:
Hisayoshi Iwakiri, Satoru Hasuike, Haruko Shimoda, Kenji Nagata, Shojiro Yamamoto, Kenichi Nakamura, Kazuya Shimoda, N Inada, Akira Kitanaka, Hiroo Abe, Arata Honda, Akira Sawaguchi, Mitsue Sueta, Yoko Kubuki, Takumi Yamaji, Yoshihiro Tahara, Tadashi Miike, Keiichi Akizuki, Ayako Kamiunten, Kotaro Shide, Masaaki Sekine, Tomonori Hidaka, Takuro Kameda
Publikováno v:
Leukemia
Mutations of calreticulin (CALR) are detected in 25-30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signa
Autor:
Samantha L. Savage, Dongqing Yan, Michael W. Deininger, Matthew S. Zabriskie, Brian J. Druker, Thomas O'Hare, Christopher A. Eide, Anthony D. Pomicter, Nadeem A. Vellore
Publikováno v:
Leukemia
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia